RU2006120483A - Скрининг-анализы и способы лечения опухоли - Google Patents
Скрининг-анализы и способы лечения опухоли Download PDFInfo
- Publication number
- RU2006120483A RU2006120483A RU2006120483/15A RU2006120483A RU2006120483A RU 2006120483 A RU2006120483 A RU 2006120483A RU 2006120483/15 A RU2006120483/15 A RU 2006120483/15A RU 2006120483 A RU2006120483 A RU 2006120483A RU 2006120483 A RU2006120483 A RU 2006120483A
- Authority
- RU
- Russia
- Prior art keywords
- tgf
- patient
- cancer
- beta
- antagonist
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 68
- 206010028980 Neoplasm Diseases 0.000 title claims 37
- 238000012106 screening analysis Methods 0.000 title 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 33
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 33
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 33
- 239000005557 antagonist Substances 0.000 claims 22
- 201000011510 cancer Diseases 0.000 claims 22
- 229940127089 cytotoxic agent Drugs 0.000 claims 21
- 206010006187 Breast cancer Diseases 0.000 claims 13
- 206010027476 Metastases Diseases 0.000 claims 13
- 208000026310 Breast neoplasm Diseases 0.000 claims 12
- 239000002246 antineoplastic agent Substances 0.000 claims 12
- 241001465754 Metazoa Species 0.000 claims 10
- 210000000988 bone and bone Anatomy 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 230000000973 chemotherapeutic effect Effects 0.000 claims 9
- 239000002254 cytotoxic agent Substances 0.000 claims 9
- 231100000599 cytotoxic agent Toxicity 0.000 claims 9
- 238000012360 testing method Methods 0.000 claims 9
- 210000004872 soft tissue Anatomy 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 8
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 7
- 230000009401 metastasis Effects 0.000 claims 7
- 101150029707 ERBB2 gene Proteins 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 238000001959 radiotherapy Methods 0.000 claims 4
- 206010065687 Bone loss Diseases 0.000 claims 3
- 239000002876 beta blocker Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 2
- 238000010171 animal model Methods 0.000 claims 2
- 201000008275 breast carcinoma Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000002919 epithelial cell Anatomy 0.000 claims 2
- 230000009422 growth inhibiting effect Effects 0.000 claims 2
- 210000005228 liver tissue Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 208000029565 malignant colon neoplasm Diseases 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 1
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000002301 combined effect Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52039803P | 2003-11-13 | 2003-11-13 | |
| US60/520,398 | 2003-11-13 | ||
| US55795104P | 2004-03-31 | 2004-03-31 | |
| US60/557,951 | 2004-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006120483A true RU2006120483A (ru) | 2007-12-20 |
Family
ID=34623132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006120483/15A RU2006120483A (ru) | 2003-11-13 | 2004-11-04 | Скрининг-анализы и способы лечения опухоли |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060015952A1 (enExample) |
| EP (1) | EP1682890A2 (enExample) |
| JP (1) | JP2007515949A (enExample) |
| KR (1) | KR20060127409A (enExample) |
| AR (1) | AR046832A1 (enExample) |
| AU (1) | AU2004292180A1 (enExample) |
| BR (1) | BRPI0416305A (enExample) |
| CA (1) | CA2542215A1 (enExample) |
| IL (1) | IL174916A0 (enExample) |
| NO (1) | NO20062715L (enExample) |
| RU (1) | RU2006120483A (enExample) |
| TW (1) | TW200526957A (enExample) |
| WO (1) | WO2005050200A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2546445A1 (en) * | 2003-11-26 | 2005-06-16 | Arqule, Inc. | Use of beta-lapachone for protecting against radiation injury |
| WO2005097832A2 (en) * | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| US7412026B2 (en) * | 2004-07-02 | 2008-08-12 | The Board Of Regents Of The University Of Oklahoma | Phase-contrast x-ray imaging systems and methods |
| US7853626B2 (en) | 2006-09-29 | 2010-12-14 | The Invention Science Fund I, Llc | Computational systems for biomedical data |
| US20080091730A1 (en) * | 2006-09-29 | 2008-04-17 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems for biomedical data |
| US8122073B2 (en) | 2006-09-29 | 2012-02-21 | The Invention Science Fund I | Computational systems for biomedical data |
| US10095836B2 (en) * | 2006-09-29 | 2018-10-09 | Gearbox Llc | Computational systems for biomedical data |
| US20080082367A1 (en) * | 2006-09-29 | 2008-04-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems for biomedical data |
| US10503872B2 (en) | 2006-09-29 | 2019-12-10 | Gearbox Llc | Computational systems for biomedical data |
| US20080082359A1 (en) * | 2006-09-29 | 2008-04-03 | Searete Llc, A Limited Liability Corporation Of State Of Delaware | Computational systems for biomedical data |
| US20080109484A1 (en) * | 2006-09-29 | 2008-05-08 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems for biomedical data |
| US10068303B2 (en) | 2006-09-29 | 2018-09-04 | Gearbox Llc | Computational systems for biomedical data |
| US10546652B2 (en) * | 2006-09-29 | 2020-01-28 | Gearbox Llc | Computational systems for biomedical data |
| US20080082583A1 (en) * | 2006-09-29 | 2008-04-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems for biomedical data |
| US8491890B2 (en) * | 2008-07-09 | 2013-07-23 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting diseases of the central nervous system |
| MX2011005967A (es) | 2008-12-05 | 2011-06-30 | Abraxis Bioscience Llc | Peptidos enlazados a sparc y usos de los mismos. |
| US20120294868A1 (en) * | 2009-04-24 | 2012-11-22 | Edwards James R | Anti-tgf-beta induction of bone cell function and bone growth |
| AU2010277554B2 (en) * | 2009-07-30 | 2015-02-19 | Antisense Pharma Gmbh | Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system |
| CN102576018A (zh) * | 2009-10-30 | 2012-07-11 | 默沙东公司 | Pcsk9免疫测定 |
| PL3117709T3 (pl) * | 2010-03-12 | 2019-01-31 | Genzyme Corporation | Terapia skojarzona do leczenia raka piersi |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| US12156912B2 (en) | 2012-05-18 | 2024-12-03 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting diseases of the central nervous system |
| KR101479543B1 (ko) * | 2013-03-15 | 2015-01-07 | 서강대학교산학협력단 | Ｔｆｇ－ｔｅｃ 융합 컨스트럭트를 이용한 종양 질환의 예방 또는 치료용 물질의 스크리닝 방법 및 이의 용도 |
| US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| BR112016024972B1 (pt) | 2014-04-27 | 2024-02-20 | Ccam Biotherapeutics Ltd | Anticorpo monoclonal humanizado, polinucleotídeo isolado,plasmídeo, composições farmacêutica e de disgnóstico, usos do dito anticorpo monoclonal humanizado e método in vitro para determinar a expressão de ceacam1 |
| WO2016100233A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| HUE070137T2 (hu) | 2014-12-15 | 2025-05-28 | Univ California | CD19-re és CD20-ra érzékeny bispecifikus VAGY-kapu kiméra antigénreceptor |
| CA3000718A1 (en) | 2015-10-02 | 2017-04-06 | Wake Forest University Health Sciences | Methods and apparatus for modeling cancer metastasis in vitro |
| HRP20230239T1 (hr) * | 2015-10-30 | 2023-04-14 | The Regents Of The University Of California | Polipeptidi koji reagiraju na transformirajući faktor rasta – beta i postupci za njihovu upotrebu |
| US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
| KR102820005B1 (ko) | 2018-02-02 | 2025-06-12 | 웨이크 포리스트 유니버시티 헬스 사이언시즈 | 면역요법 관련 오가노이드 및 그의 제조 및 사용 방법 |
| SG11202012148RA (en) * | 2018-08-21 | 2021-01-28 | Albert Einstein College Medicine | Monoclonal antibodies against human tim-3 |
| WO2020124084A1 (en) * | 2018-12-15 | 2020-06-18 | The Brigham And Women's Hospital, Inc. | Augmented digital microscopy for lesion analysis |
| CN111088227A (zh) * | 2019-12-31 | 2020-05-01 | 广州航华生物医药科技有限公司 | 一种细胞分离培养液和t细胞分离培养的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000001410A1 (en) * | 1998-07-06 | 2000-01-13 | Beth Israel Deaconess Medical Center | Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis |
| US20010046502A1 (en) * | 2000-02-04 | 2001-11-29 | The Board Of Trustees Of The University Of Illinois | Animal model for testing immunotherapies of spontaneous metastatic disease |
| AU2001233246A1 (en) * | 2000-02-04 | 2001-08-14 | California Pacific Medical Center Research Institute | Novel use of ribozymes to block gene expression |
| CA2298737A1 (en) * | 2000-02-10 | 2001-08-10 | Manikkam Suthanthiran | 2167334tgf-.beta. antagonists to inhibit tumor cell formation or progression |
| US6632979B2 (en) * | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US6767541B2 (en) * | 2000-03-20 | 2004-07-27 | The Regents Of The University Of California | HER-2/neu overexpression abrogates growth inhibitory pathways |
| US20030125251A1 (en) * | 2001-06-21 | 2003-07-03 | Wakefield Lalage M. | Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta |
-
2004
- 2004-11-04 AU AU2004292180A patent/AU2004292180A1/en not_active Abandoned
- 2004-11-04 US US10/981,356 patent/US20060015952A1/en not_active Abandoned
- 2004-11-04 RU RU2006120483/15A patent/RU2006120483A/ru not_active Application Discontinuation
- 2004-11-04 KR KR1020067011504A patent/KR20060127409A/ko not_active Withdrawn
- 2004-11-04 BR BRPI0416305-2A patent/BRPI0416305A/pt not_active IP Right Cessation
- 2004-11-04 JP JP2006539632A patent/JP2007515949A/ja not_active Withdrawn
- 2004-11-04 EP EP04810283A patent/EP1682890A2/en not_active Withdrawn
- 2004-11-04 CA CA002542215A patent/CA2542215A1/en not_active Abandoned
- 2004-11-04 WO PCT/US2004/036651 patent/WO2005050200A2/en not_active Ceased
- 2004-11-05 AR ARP040104077A patent/AR046832A1/es unknown
- 2004-11-05 TW TW093133935A patent/TW200526957A/zh unknown
-
2006
- 2006-04-10 IL IL174916A patent/IL174916A0/en unknown
- 2006-06-12 NO NO20062715A patent/NO20062715L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL174916A0 (en) | 2006-08-20 |
| AU2004292180A2 (en) | 2005-06-02 |
| TW200526957A (en) | 2005-08-16 |
| AR046832A1 (es) | 2005-12-28 |
| NO20062715L (no) | 2006-08-11 |
| US20060015952A1 (en) | 2006-01-19 |
| WO2005050200A9 (en) | 2005-08-18 |
| WO2005050200A2 (en) | 2005-06-02 |
| JP2007515949A (ja) | 2007-06-21 |
| CA2542215A1 (en) | 2005-06-02 |
| AU2004292180A1 (en) | 2005-06-02 |
| BRPI0416305A (pt) | 2007-01-09 |
| EP1682890A2 (en) | 2006-07-26 |
| WO2005050200A3 (en) | 2005-12-01 |
| KR20060127409A (ko) | 2006-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006120483A (ru) | Скрининг-анализы и способы лечения опухоли | |
| JP2007515949A5 (enExample) | ||
| JP3699399B2 (ja) | 癌治療への応答を決定する方法 | |
| Owen | Bone tumours in man and animals | |
| US8144966B2 (en) | Use of endogenous fluorescence to identify invading metastatic breast tumor cells | |
| Martano et al. | Canine oral fibrosarcoma: Changes in prognosis over the last 30 years? | |
| Hassan et al. | Feline mammary cancer: Novel nude mouse model and molecular characterization of invasion and metastasis genes | |
| Brewer et al. | Spinal cord nephroblastoma in dogs: 11 cases (1985–2007) | |
| Spiguel | Soft tissue sarcomas | |
| Meazza et al. | What is the best clinical approach to recurrent/refractory osteosarcoma? | |
| US9714453B2 (en) | Method for detecting genes sensitive to low-level ionizing radiation | |
| JP2019144254A (ja) | Ｐｓｍａ上昇により致死性前立腺癌が同定される | |
| JP2016501027A (ja) | 患者テーラーメイド型抗癌剤スクリーニング用システム | |
| KR20200131837A (ko) | 순환 세포를 이용하여 개체에서 치료 반응 및 질병 진행을 모니터링하는 방법 | |
| US20190351076A1 (en) | Tumor cell xenograft model in zebrafish, and methods of constructing and using the same | |
| Marques et al. | Low doses of ionizing radiation activate endothelial cells and induce angiogenesis in peritumoral tissues | |
| Warren | The physiological effects of roentgen radiation upon normal body tissues | |
| Xu et al. | Detecting metastatic potential of cancer through longitudinal vasculature imaging of biomaterial scaffold using non-invasive in vivo photoacoustic microscopy and optical coherence tomography | |
| Schiffer et al. | Pathology of human malignant gliomas after radiation and chemotherapy | |
| Wouters et al. | Skin and subcutaneous tumors | |
| Samuel et al. | Investigating the effects of stereotactic body radiation therapy on pancreatic tumor hypoxia and microvasculature in an orthotopic mouse model using intravital fluorescence microscopy | |
| Roser et al. | Apoptosis, vascularity, and proliferation in primary central nervous system lymphomas (PCNSL): a histopathological study | |
| Pastushenko et al. | Lymphangiogenesis: implications for diagnosis, treatment, and prognosis in patients with melanoma | |
| EP3447496A1 (en) | Injection composition for labeling lesion | |
| RU2341794C1 (ru) | Способ прогнозирования эффективности химиотерапии у больных со злокачественными глиомами |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090504 |